(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 480.57% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.19%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.42%.
Humacyte's revenue in 2026 is $1,571,000.On average, 9 Wall Street analysts forecast HUMA's revenue for 2026 to be $4,485,335,409, with the lowest HUMA revenue forecast at $2,024,028,437, and the highest HUMA revenue forecast at $8,775,908,645. On average, 8 Wall Street analysts forecast HUMA's revenue for 2027 to be $17,515,861,196, with the lowest HUMA revenue forecast at $9,176,294,729, and the highest HUMA revenue forecast at $30,124,464,696.
In 2028, HUMA is forecast to generate $64,943,821,410 in revenue, with the lowest revenue forecast at $31,708,780,072 and the highest revenue forecast at $130,194,767,786.